CORT NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Corcept Therapeutics Incorporated · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 114.5 USD
20.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 100.0% above the Trend Line and sits at 91.7% of its 52-week range. The latest completed week returned 20.1%, after a 26.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is expensive relative to peers. Options positioning is volatility with 46/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: price is close to its 52-week high.

Setup score 72 out of 100
Latest Close 114.5 USD 31 Jul 2026
1W Return 20.1% latest completed week
4W Return 26.9% short-term follow-through
12W Return 119.0% quarterly tape
Trend Breadth 51.9% 27 of 52 weeks active
Volume Ratio 1.8x vs 13-week average
What is working
  • The trend backdrop is active with a 6-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 11 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 20.1% Latest completed week; four-week move 26.9%. Indicator stack 49/81 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 56.85% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 46/100 conviction; expected move 9.9%. News sentiment 56/100 60 relevant articles in the latest sentiment read. Event risk 30 Jul Latest stored earnings date was 30 Jul 2026.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 100.0% above the Trend Line and sits at 91.7% of its 52-week range. The latest completed week returned 20.1%, after a 26.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8712-week average 0.51

12-week confirmation

Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.87Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1111 reversal markers

No recent accumulation markers. 11 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 26.9% over four weeks, 119.0% over 12 weeks, and 65.9% over one year. The current trend has remained active for 6 consecutive weeks.

Performance by holding period

1W20.1%
4W26.9%
12W119.0%
26W187.2%
52W65.9%
Active trend streak6 weeks
Active weeks in one year27
Trend breadth51.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.66Latest activity-pressure read.
Pressure change16.2%Four-week change in activity pressure.
Leadership62.02Latest relative-leadership reading.
RS change151.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength24/100Blend of value, momentum, and quality. Underlying universe rank 77; rank 1 is best.
Value1/100Relative valuation strength. Underlying universe rank 100; rank 1 is best.
Quality71/100Profitability and accounting quality. Underlying universe rank 30; rank 1 is best.
Momentum79/100Medium-term price momentum. Underlying universe rank 22; rank 1 is best.
Growth8/100Revenue and earnings growth. Underlying universe rank 93; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
213.7x
Price divided by trailing earnings.
Price / sales
13.3x
Market value relative to trailing revenue.
EV / EBITDA
716.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
1.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
98.3%
Gross profit retained from each unit of revenue.
Operating margin
1.6%
Operating profit retained from revenue.
Free-cash-flow margin
15.7%
Free cash flow generated from revenue.
Return on invested capital
1.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
12.2%
Latest one-year revenue growth.
EPS growth
-64.0%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-33.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-7.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

CORT shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 3.73, expected move of 9.9%, and Sharemaestro trend signal active.

Conviction46/100
Expected move9.9%
Put/call volume3.73
Pressure-50
Speculation41
Volatility76
Trend agreement32
Open options detail
Insider activity4 / 16

4 acquisitions and 16 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 60 relevant articles.

20 positive · 32 neutral · 8 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings30 JulLatest stored earnings date was 30 Jul 2026.
Options expected move9.9%Nearest-chain priced movement where available.
52-week drawdown-6.3%Distance below the 52-week high.
13-week volatility6.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher18 of 268 weeks finished lower.
Best week+20.1%Week of 31 Jul.
Worst week-12.9%Week of 20 Feb.
Latest week+20.1%Week of 31 Jul.

Shape of recent returns

Strong gains13
Modest gains5
Flat weeks0
Modest losses5
Sharp losses3
Recent vol6.6%13-week weekly-return volatility.
Base vol10.9%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew7.1% / -6.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape67/100

Trend, activity pressure, participation, and risk combine to a 67/100 tape read.

 Indicator analysis64/100

Latest 12-week confirmation: trend 6/12, activity pressure 12/12, relative leadership 9/12.

Activity pressure 0.87; 11 reversal markers Next-Week ExpectancyPositive 56.85%

Next-week expectancy is positive with a 56.85% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors42/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 56; Small Cap Core rank 100 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

CORT shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 3.73, expected move of 9.9%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 9.9% Sentiment56/100

Weighted news tone is neutral across 60 relevant articles.

Corcept Therapeutics (CORT) affiliate files to sell 40,000 shares after option exercise Insiders4 / 16

4 acquisitions and 16 disposals in the latest 180-day insider tape.

 Earnings30 Jul

Latest stored earnings date was 30 Jul 2026.

 Research flow1 items

0 recent research articles and 1 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026114.5 USD20.1%57.24 USD50.36 USD1.6662.0210.1MOn
24 Jul 202695.36 USD5.3%54.70 USD49.83 USD1.6036.755.8MOn
17 Jul 202690.52 USD-1.5%54.28 USD49.38 USD1.6028.186.3MOn
10 Jul 202691.88 USD1.9%54.05 USD48.95 USD1.5124.785.7MOn
3 Jul 202690.21 USD3.3%53.92 USD48.51 USD1.4324.643.4MOn
26 Jun 202687.32 USD9.3%53.78 USD48.07 USD1.3521.605.3MOn
19 Jun 202679.91 USD-3.6%53.52 USD47.66 USD1.226.074.5MOff
12 Jun 202682.91 USD14.2%53.43 USD47.28 USD1.0912.395.2MOff
5 Jun 202672.62 USD4.5%53.19 USD46.90 USD0.960.374.6MOff
29 May 202669.49 USD15.4%53.22 USD46.58 USD0.85-8.784.5MOff
22 May 202660.22 USD6.8%53.36 USD46.29 USD0.76-19.504.8MOff
15 May 202656.37 USD7.8%53.77 USD46.05 USD0.68-24.727.2MOff
8 May 202652.28 USD1.7%54.51 USD45.85 USD0.59-31.226.1MOff
1 May 202651.42 USD11.6%55.23 USD45.66 USD0.49-29.537.1MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.